

News Release

Newport Beach, CA – February 23, 2022



ImmunogenX to Make Highlighted Presentations at DDW 2022

Outstanding clinical trial results to be presented at Major Medical Meeting

Based on the results obtained from the CeliacShield™ trial (NCT03585478) by ImmunogenX, Inc. and conducted at the Mayo Clinic, the work has been selected as a Lecture Presentation at the 2022 Digestive Disease Week® (DDW) Conference, the foremost gastroenterological event in the world, being held at the San Diego Convention Center, San Diego, CA on May 21-24. The presentation entitled:

“CeliacShield™ Gluten Challenge Study – Latiglutenase Protects the Mucosa and Attenuates Symptoms of Celiac Disease”

was authored by Joseph Murray MD of Mayo Clinic and Jack Syage PhD and CEO of ImmunogenX on behalf of the CeliacShield study team. The talk will be delivered in the session “Separating the Wheat from the Chaff: Top Clinical Abstracts in Celiac Disease,” on May 24, 2022 from 2:00 pm to 3:30 pm PDT.

As a further testament to the substantial impact of the CeliacShield trial, our work was also selected as a Poster of Distinction entitled:

“Gluten in Urine Measurements Validate Latiglutenase Mechanism of Action in CeliacShield™ Gluten Challenge Study”

This work was co-authored by Jennifer Sealey-Voyksner PhD (CSO) and Jack Syage PhD (CEO) of ImmunogenX. The poster will be presented in the session “Celiac Disease and Gluten Related Disorders” on May 21, 2022 from 12:30 pm to 1:30 pm PDT.

The CeliacShield study, funded by a grant from the National Institutes of Health (NIH) National Center for Complementary and Integrative Health (NCCIH)* to ImmunogenX, measured several outcomes including histology, symptoms, serology, and gluten in urine, which consistently met or exceeded expectations for clinical and statistical significance.

Dr. Jack Syage, CEO remarks “Our team was very pleased to undertake this clinical study and are gratified to see such positive results. Latiglutenase continues to be well tolerated and the results look promising for offering significant benefit to people suffering from celiac disease.”

** The content of this news release is solely the responsibility of ImmunogenX and does not necessarily represent the official views of the National Institutes of Health.*

About ImmunogenX

ImmunogenX, Inc. is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. www.immunogenx.com

For further information please contact

Matthew Dickason, MBA
Chief Operating Officer
(949) 679-0900

mdickason@immunogenx.com